VOYA Investment Management
TRVI icon

VOYA Investment Management’s Trevi Therapeutics TRVI Stock Holding History

VOYA Investment Management’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.74M Buy
93,562
+49,205
+111% +$716K ﹤0.01% 1297
2026
Q1 		$529K Sell
44,357
-181,858
-80% -$2.04M ﹤0.01% 1691
2025
Q4 		$2.83M Buy
226,215
+211,035
+1,390% +$2.44M ﹤0.01% 1071
2025
Q3 		$139K Sell
15,180
-6,365
-30% -$47.7K ﹤0.01% 2253
2025
Q2 		$118K Buy
21,545
+1,715
+9% +$10.7K ﹤0.01% 2454
2025
Q1 		$125K Sell
19,830
-1,059
-5% -$5.05K ﹤0.01% 2383
2024
Q4 		$86.1K Sell
20,889
-1,333
-6% -$4.27K ﹤0.01% 2607
2024
Q3 		$74.2K Sell
22,222
-212
-0.9% -$630 ﹤0.01% 2716
2024
Q2 		$66.9K Buy
22,434
+9,160
+69% +$25.5K ﹤0.01% 2754
2024
Q1 		$45.8K Buy
+13,274
New +$29.6K ﹤0.01% 2738
2023
Q4 		– Sell
-17,460
Closed -$38.1K – 2921
2023
Q3 		$38.1K Hold
17,460
– – ﹤0.01% 2878
2023
Q2 		$41.7K Buy
+17,460
New +$44K ﹤0.01% 2911

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

VOYA Investment Management's TRVI Position: Q2 2026 in Review

VOYA Investment Management increased its Trevi Therapeutics (TRVI) stake by 111% in Q2 2026, buying an estimated $716K and bringing the position to 93,562 shares worth $1.74M. The position accounts for ﹤0.01% of the portfolio, ranked #1297.

VOYA Investment Management first reported a position in TRVI in Q2 2023 and has held it in 12 quarters since. The position peaked at $2.83M in Q4 2025. 217 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • VOYA Investment Management held 93,562 shares of Trevi Therapeutics worth $1.74M as of Q2 2026.
  • VOYA Investment Management bought 49,205 Trevi Therapeutics shares in Q2 2026, an estimated $716K.
  • Trevi Therapeutics made up ﹤0.01% of VOYA Investment Management's portfolio in Q2 2026, its #1297 holding.
  • VOYA Investment Management first reported a position in Trevi Therapeutics in Q2 2023 and has held it in 12 quarters since.
  • VOYA Investment Management's Trevi Therapeutics position peaked at $2.83M in Q4 2025.
  • 217 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on VOYA Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.